↓ Skip to main content

Dove Medical Press

Role of zoledronic acid in the prevention and treatment of osteoporosis

Overview of attention for article published in Clinical Interventions in Aging, March 2011
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
33 Dimensions

Readers on

mendeley
93 Mendeley
Title
Role of zoledronic acid in the prevention and treatment of osteoporosis
Published in
Clinical Interventions in Aging, March 2011
DOI 10.2147/cia.s7282
Pubmed ID
Authors

Louis-Georges Ste-Marie, Ages Rakel, Andree Boucher, Louis-Georges Ste-Marie

Abstract

Taken once a year, intravenous zoledronic acid (Zol) (Reclast® or Aclasta®) is a third-generation nitrogen-containing bisphosphonate that is effective compared with placebo in reducing the risk of fractures in patients with postmenopausal osteoporosis and recent low-trauma hip fracture. In glucocorticoid-induced osteoporosis, there is no significant difference between Zol and risedronate for new fractures. Improvements in bone mineral density and early reduction of bone remodeling markers are observed in postmenopausal osteoporosis, recent low-trauma hip fracture, and glucocorticoid-induced osteoporosis. Given that Zol is generally well tolerated and very convenient, it is an interesting therapeutic option for aging patients who take multiple oral drugs, who have adherence or gastrointestinal tolerance issues, and who have an indication for oral bisphosphonates. Zol is not recommended for patients with severe renal impairment. Vitamin D deficiency should be corrected before the administration of Zol.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 93 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
Unknown 92 99%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 13 14%
Student > Ph. D. Student 12 13%
Researcher 11 12%
Student > Master 11 12%
Other 10 11%
Other 17 18%
Unknown 19 20%
Readers by discipline Count As %
Medicine and Dentistry 36 39%
Biochemistry, Genetics and Molecular Biology 11 12%
Agricultural and Biological Sciences 6 6%
Engineering 6 6%
Pharmacology, Toxicology and Pharmaceutical Science 4 4%
Other 9 10%
Unknown 21 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 May 2014.
All research outputs
#22,758,309
of 25,371,288 outputs
Outputs from Clinical Interventions in Aging
#1,779
of 1,968 outputs
Outputs of similar age
#113,322
of 120,079 outputs
Outputs of similar age from Clinical Interventions in Aging
#3
of 3 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,968 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 120,079 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.